Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models.
Corleis B, Hoffmann D, Rauch S, Fricke C, Roth N, Gergen J, Kovacikova K, Schlottau K, Halwe NJ, Ulrich L, Schön J, Wernike K, Widera M, Ciesek S, Mueller SO, Mettenleiter TC, Maione D, Petsch B, Beer M, Dorhoi A. Corleis B, et al. Among authors: mueller so. Nat Commun. 2023 Feb 13;14(1):816. doi: 10.1038/s41467-023-36110-1. Nat Commun. 2023. PMID: 36781853 Free PMC article.
CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2.
Hoffmann D, Corleis B, Rauch S, Roth N, Mühe J, Halwe NJ, Ulrich L, Fricke C, Schön J, Kraft A, Breithaupt A, Wernike K, Michelitsch A, Sick F, Wylezich C, Hoffmann B, Thran M, Thess A, Mueller SO, Mettenleiter TC, Petsch B, Dorhoi A, Beer M. Hoffmann D, et al. Among authors: mueller so. Nat Commun. 2021 Jun 30;12(1):4048. doi: 10.1038/s41467-021-24339-7. Nat Commun. 2021. PMID: 34193869 Free PMC article.
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial.
Kremsner PG, Mann P, Kroidl A, Leroux-Roels I, Schindler C, Gabor JJ, Schunk M, Leroux-Roels G, Bosch JJ, Fendel R, Kreidenweiss A, Velavan TP, Fotin-Mleczek M, Mueller SO, Quintini G, Schönborn-Kellenberger O, Vahrenhorst D, Verstraeten T, Alves de Mesquita M, Walz L, Wolz OO, Oostvogels L; CV-NCOV-001 Study Group. Kremsner PG, et al. Among authors: mueller so. Wien Klin Wochenschr. 2021 Sep;133(17-18):931-941. doi: 10.1007/s00508-021-01922-y. Epub 2021 Aug 10. Wien Klin Wochenschr. 2021. PMID: 34378087 Free PMC article. Clinical Trial.
Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine.
Gebre MS, Rauch S, Roth N, Yu J, Chandrashekar A, Mercado NB, He X, Liu J, McMahan K, Martinot A, Martinez DR, Giffin V, Hope D, Patel S, Sellers D, Sanborn O, Barrett J, Liu X, Cole AC, Pessaint L, Valentin D, Flinchbaugh Z, Yalley-Ogunro J, Muench J, Brown R, Cook A, Teow E, Andersen H, Lewis MG, Boon ACM, Baric RS, Mueller SO, Petsch B, Barouch DH. Gebre MS, et al. Among authors: mueller so. Nature. 2022 Jan;601(7893):410-414. doi: 10.1038/s41586-021-04231-6. Epub 2021 Nov 18. Nature. 2022. PMID: 34794169 Free PMC article.
mRNA vaccines induce rapid antibody responses in mice.
Gebre MS, Rauch S, Roth N, Gergen J, Yu J, Liu X, Cole AC, Mueller SO, Petsch B, Barouch DH. Gebre MS, et al. Among authors: mueller so. NPJ Vaccines. 2022 Aug 1;7(1):88. doi: 10.1038/s41541-022-00511-y. NPJ Vaccines. 2022. PMID: 35915094 Free PMC article.
A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses.
Lenart K, Hellgren F, Ols S, Yan X, Cagigi A, Cerveira RA, Winge I, Hanczak J, Mueller SO, Jasny E, Schwendt K, Rauch S, Petsch B, Loré K. Lenart K, et al. Among authors: mueller so. Mol Ther Methods Clin Dev. 2022 Dec 8;27:309-323. doi: 10.1016/j.omtm.2022.10.001. Epub 2022 Oct 6. Mol Ther Methods Clin Dev. 2022. PMID: 36217434 Free PMC article.
59 results